Myelin Oligodendrocyte Glycoprotein antibody-associated disease (MOGAD): Optic Neuritis

Update Item Information
Identifier panse-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-MOGAD-optic-neuritis
Title Myelin Oligodendrocyte Glycoprotein antibody-associated disease (MOGAD): Optic Neuritis
Creator Ketaki Panse, MD, Resident Physician, University of California, Davis; Akash Virupakshaiah, MD, Clinical Fellow, University of California, San Francisco; Yin Allison Liu, MD, PhD, Assistant Professor of Neuro-Ophthalmology, University of California, Davis
Subject Myelin Oligodendrocyte Glycoprotein antibody disease; optic neuritis; pediatric optic neuritis
Description We present a case of a 12 year old patient with no past medical history with one week of acute vision loss bilaterally. She was found to have bilateral severe optic disc edema, and MRI showed evidence of bilateral optic neuritis. MOG IgG serum testing returned positive, and the patient was diagnosed with Myelin Oligodendrocyte Glycoprotein antibody-associated disease (MOGAD) optic neuritis. She was treated initially with intravenous corticosteroids, and then with therapeutic plasmapheresis. At her two week clinic follow up, her vision had returned to baseline, and on examination she had trace temporal disc pallor of the right eye, with resolution of her optic disc edema bilaterally. This case illustrates characteristic features, diagnostic criteria, and treatment options for MOGAD in a pediatric patient.
Date 2023-06
References [1] Horton L, Bennett JL. Acute management of optic neuritis: An evolving paradigm. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 38(3):358-367; [2.Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, Lopez-Chiriboga AS, Pittock SJ, Flanagan EP. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol. 2022 Jun 17;13:885218. doi: 10.3389/fneur.2022.885218. PMID: 35785363; PMCID: PMC9247462.; [3] Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89-102. doi:10.1038/s41582-018-0112; [4] Shor N, Aboab J, Maillart E, et al. Clinical, imaging and follow‐up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentrestudy of 62 adult patients. EurJ Neurol. 2020;27(2):384-391. doi:10.1111/ene.14089; [5] DucloyerJ-B, CaignardA, Aidaoui R, et al. MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis. Br J Ophthalmol. October 2019:bjophthalmol-2019-314845. doi:10.1136/bjophthalmol-2019-314845; [6] in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius S, Ruprecht K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. doi:10.1186/s12974-016-0718-0
Language eng
Format application/pdf
Format Creation Created in Microsoft PowerPoint
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Spencer S. Eccles Health Sciences Libary
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah, 10 N 1900 E SLC, UT 84112-5890
Rights Management Copyright 2023. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6nwdzc8
Setname ehsl_novel_yal
ID 2296017
Reference URL https://collections.lib.utah.edu/ark:/87278/s6nwdzc8
Back to Search Results